Who Are the Core Customers in Totally Company's Target Market?

The core Totally Company target market comprises the 42 Integrated Care Boards (ICBs) across England and the Health Service Executive (HSE) in the Republic of Ireland. These institutional commissioners control local urgent care, elective surgery, and community health budgets and drive procurement decisions that generate the largest contracts and recurrent revenue streams for Totally plc; winning procurement leads and clinical directors is critical.

NHS Foundation Trusts use Totally plc for insourcing to increase theatre utilization and cut waiting lists; these trusts represent a meaningful secondary revenue channel. A smaller but growing segment includes corporate clients and private individuals paying for elective procedures via specialist clinics to bypass long public-sector wait times.

Totally plc mainly serves institutions – public healthcare commissioners and hospital trusts – while also operating a mixed model that accommodates B2B contracts and direct-to-patient elective services. This hybrid approach lets Totally plc convert institutional volume into clinic-level throughput and fee income.

The most valuable segment is clearly the 42 ICBs and the HSE: they control population-level budgets and award multi-year contracts that accounted for the majority of Totally plc's public-sector revenue in fiscal 2025. Targeting procurement leads and clinical directors yields the highest contract value per account and largest long-term utilization gains; see related context in Mission, Vision, and Values of Totally Company.

Totally Company target market is concentrated in high-density urban areas where NHS 111 and Urgent Treatment Centre volumes remain largest; these contracts drove the bulk of urgent-care throughput in 2025 as A&E overcrowding persisted.

Northern England and the Midlands show the widest supply-demand gap; elective demand is strongest in ophthalmology, orthopedics, and diagnostic imaging where Totally Company can deliver high volumes at lower cost-per-case versus acute hospitals.

Totally Company core customers are driven by NHS 111/UTC referrals and elective pathways; in 2025 these contracts represented the largest revenue and usage share, with UTC activity accounting for an estimated ~40% of urgent-care visits in key contracts.

Elective volumes grew fastest in 2025 in ophthalmology and orthopedics (diagnostic imaging referrals up >10% year-over-year in some regions); the Republic of Ireland is a high-growth market as policy shifts decentralise care into community settings. See Competitive Landscape of Totally Company for context: Competitive Landscape of Totally Company

Totally plc wins new ICB contracts by proving clinical outcomes and cost savings with data-driven case studies, and broadens its Totally Company target market by offering bolt-on services that convert elective and urgent-care pathways into cross-sell opportunities.

Retention exceeds 90 percent in the 2025 fiscal year due to long-term contracting, measurable clinical KPIs, and contractual SLAs; tight ICB budgets increase focus on verified savings, so proving value reduces churn.

Repeat demand comes from non-discretionary 24/7 urgent care and elective backlog services that form a defensive revenue floor, while bolt-on dermatology and physiotherapy deepen revenue per ICB and increase renewal propensity.

The biggest growth lever is the capital-light insourcing model, which grew an estimated 12 percent in 2025 as Totally plc clinical teams used NHS downtime – this drives scalable expansion into Totally Company core customers and reduces capital intensity.